In our study of HMGB1 as a predictive and prognostic biomarker of oncolytic immunotherapy, a concentration of 0.512 ng/mL was determined as the cutoff for categorizing patients into low and high HMGB1 baseline groups in various types of cancer [24]. Here, HMGB1 is linked to cancer.